Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill amends section 1106(b) of the Public Health Service Act to reauthorize and modify a sickle cell disease prevention and treatment demonstration program. It revises program language to emphasize treatment of sickle cell disease and prevention and treatment of its complications, expands allowable award instruments (grants, contracts, cooperative agreements), and increases authorized funding to $8,205,000 per year for fiscal years 2025–2029.
Liberal emphasizes equity and stronger program design requirements
Narrow, low-cost health reauthorization likely attracts bipartisan support but needs floor time and committee approval.
This bill amends section 1106(b) of the Public Health Service Act to reauthorize and modify a sickle cell disease prevention and treatment demonstration program.
It revises program language to emphasize treatment of sickle cell disease and prevention and treatment of its complications, expands allowable award instruments (grants, contracts, cooperative agreements), and increases authorized funding to $8,205,000 per year for fiscal years 2025–2029.
The bill also includes a Sense of Congress encouraging further research into causes and cures for heritable blood disorders, including sickle cell disease.
Content is noncontroversial and small-dollar; procedural hurdles and competing priorities reduce guaranteed passage likelihood.
How solid the drafting looks.
Liberal emphasizes equity and stronger program design requirements
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberal emphasizes equity and stronger program design requirements
Likely supportive because it increases federal funding and explicitly targets complications of sickle cell disease, a condition with racial health equity implications.
Sees the Sense of Congress and expanded authority as helpful steps toward research, surveillance, and improved care for a historically underfunded community.
Generally positive toward a focused, bipartisan public-health measure that modestly increases resources.
Views the bill as pragmatic but would want clearer implementation details, measurable outcomes, and assurance against duplication with existing federal programs.
Cautiously receptive on humanitarian grounds but wary of increased federal spending and program expansion.
May support targeted research and treatment funding but wants fiscal oversight, limited scope, and protection of state roles.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is noncontroversial and small-dollar; procedural hurdles and competing priorities reduce guaranteed passage likelihood.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes equity and stronger program design requirements
Content is noncontroversial and small-dollar; procedural hurdles and competing priorities reduce guaranteed passage likelihood.
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Sickle Cell Disease and Other Heritable Blood Disorders Resear…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.